Site icon pharmaceutical daily

Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across the:

With six approved drugs, namely POLIVY (2019), LUMOXITI (2018), BESPONSA (2017), MYLOTARG (2017, reapproval), KADCYLA (2013) and ADCETRIS (2011), and more than 200 in the pipeline (clinical/preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics.

The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells/pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next-generation conjugation technologies use artificially integrated lysine/cysteine residues in order to improve the DAR of the resulting conjugate.

Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

It is worth highlighting that multiple licensing agreements/collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups/small companies, offering novel conjugation technologies, more potent cytotoxins/warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years.

In addition to other elements, the report includes:

In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Topics Covered

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Antibody-based Therapeutics

3.3 Antibody Drug Conjugates (ADCs)

3.3.1 Components of ADCs

3.3.1.1 Antibody

3.3.1.2 Cytotoxin

3.3.1.3 Linker

3.4. Advantages of ADCs over Traditional Pharmacological Interventions

3.5. ADC Linker Technologies

3.5.1. Non-cleavable Linkers

3.5.2. Cleavable Linkers

3.6. ADC Conjugation Technologies

3.6.1. Chemical Conjugation

3.6.2. Enzymatic Conjugation

3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE

4.1. Chapter Overview

4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape

4.2.1. Analysis by Type of Technology

4.2.2. Analysis by ADC Generation

4.2.3. Analysis by Type of Linker

4.2.4. Analysis by Type of Conjugation

4.2.5. Analysis by Site Specificity

4.2.6. Analysis by Drug to Antibody Ratio

4.2.7. Analysis by Patent Availability

4.2.8. Analysis by Licensing Activity

4.3. ADC Linker and Conjugation Technologies: Developer Landscape

4.3.1 Analysis by Year of Establishment

4.3.2 Analysis by Company Size

4.3.3 Analysis by Geographical Location

4.3.4 Leading ADC Developers: Analysis by Number of Technologies

4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location

4.3.6 World Map Representation: Analysis by Geography

4.4 ADC Linker and Conjugation Technologies: Service Providers

5. COMPANY PROFILES

5.1 Chapter Overview

5.2 Key Players in North America

5.2.1 Ambrx

5.2.1.1 Company Overview

5.2.1.2 Technology Overview

5.2.1.3 Recent Developments and Future Outlook

5.2.2 Catalent Biologics

5.2.3 Immunomedics

5.2.4 Mersana Therapeutics

5.2.5 Seattle Genetics

5.2.6 Sutro Biopharma

5.3 Key Players in Europe and Asia

5.3.1 Iksuda Therapeutics

5.3.2 LegoChem Biosciences

5.3.3 LinXis

5.3.4 NBE Therapeutics

6. PARTNERSHIPS AND COLLABORATIONS

6.1 Chapter Overview

6.2 Partnership Models

6.3 List of Partnerships and Collaborations

6.3.1 Analysis by Year of Partnership

6.3.2 Analysis by Type of Partnership

6.3.3 Analysis by Type of Linker

6.3.4 Analysis by Type of Conjugation

6.3.5 Analysis by Year of Partnership and Type of Partner

6.3.6 Analysis by Type of Partnership and Type of Partner

6.3.7 Most Active Players: Analysis by Number of Partnerships

6.3.8 Most Popular Technologies: Analysis by Number of Partnerships

6.3.9 Regional Analysis

6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNERS ANALYSIS

7.1 Chapter Overview

7.2 Scope and Methodology

7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America

7.3.1 Most Likely Partners

7.3.2 Likely Partners

7.3.3 Less Likely Partners

7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe

7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

8.1 Chapter Overview

8.2 Methodology

8.3 Assumptions and Key Parameters

8.4 Technology Competitiveness Analysis

8.4.1 Technologies Developed by Companies based in North America

8.4.2 Technologies Developed by Companies based in Europe

8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW

9. PATENT ANALYSIS

9.1 Chapter Overview

9.2 Scope and Methodology

9.3 ADC Linker and Conjugation Technologies: Patent Portfolio

9.3.1 Analysis by Publication Year

9.3.2 Analysis by Issuing Authority / Patent Offices Involved

9.3.3 Analysis by CPC Symbols

9.3.4 Emerging Focus Areas

9.3.5 Analysis by Type of Company / Organization

9.3.6 Leading Assignees: Analysis by Number of Patents

9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis

9.4.1 Analysis by Patent Characteristics

9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis

10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS

10.1 Chapter Overview

10.2 First Generation ADC Technologies

10.3 Second Generation ADC Technologies

10.3.1 Cysteine and Selenocysteine Engineering

10.3.2 Unnatural Amino Acid Engineering

10.3.3 Amino-Terminal Serine Engineering

10.4 Third Generation ADC Technologies

10.4.1 Enzyme-Assisted Ligation Approaches

10.4.2 Glycan Remodeling Approaches

10.4.3 Ligation at Fab Nucleotide-Binding Site

10.4.4 Cysteine Rebridging

10.4.5 Avoiding or Limiting Retro-Michael Drug Deconjugation

10.5 Evolutionary Analysis

11. MARKET SIZING AND FORECAST

11.1 Chapter Overview

11.2 Forecast Methodology and Key Assumptions

11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030

11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030

11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030

11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030

11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030

11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030

11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030

11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030

12. EXECUTIVE INSIGHTS

12.1 Chapter Overview

12.2 Miracogen

12.2.1 Company Snapshot

12.2.2 Interview Transcript: Mary Hu, Chief Executive Officer

12.3 NBE Therapeutics

12.4 Synaffix

12.5 EUCODIS Bioscience

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/jl2lc9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version